review
avail
clinic
laboratori
data
fourteen
patient
treat
hospit
mer
outbreak
patient
classifi
four
group
base
sever
mortal
tabl
supplementari
fig
supplementari
tabl
group
patient
includ
two
patient
develop
fever
recov
without
develop
pneumonia
recov
without
treatment
group
ii
includ
three
patient
develop
mild
pneumonia
without
hypoxemia
tabl
supplementari
tabl
show
elev
creactiv
protein
crp
mgdl
elev
level
aspart
aminotransferas
ast
alanin
aminotransferas
alt
lactat
dehydrogenas
ldh
supplementari
tabl
four
patient
recov
prolong
sever
pneumonia
classifi
group
iii
sever
pneumonia
defin
pneumonia
sever
index
psi
initi
present
tabl
patient
group
exhibit
elev
liver
enzym
proteinuria
acut
phase
among
pneumonia
rapidli
progress
respiratori
failur
requir
mechan
ventil
mv
extracorpor
membran
oxygen
ecmo
also
receiv
convalesc
plasma
therapi
twice
day
symptom
onset
supplementari
fig
group
iv
includ
five
fatal
case
group
iv
patient
suffer
sever
pneumonia
ard
requir
high
flow
nasal
cannula
andor
mechan
ventil
deceas
patient
older
except
underli
ill
except
decompens
liver
cirrhosi
poorli
control
blood
glucos
level
merscov
infect
diagnos
activ
pulmonari
tuberculosi
one
week
encount
merscov
infect
patient
develop
pneumonia
two
day
onset
fever
progress
ard
within
week
comorbid
includ
chronic
pulmonari
obstruct
diseas
copd
asthma
infect
merscov
treat
acut
exacerb
pulmonari
diseas
die
within
week
symptom
onset
despit
mechan
ventil
patient
pneumonia
treat
antivir
drug
supplementari
tabl
examin
daili
chest
xray
resolut
pneumonia
repres
radiolog
find
mer
patent
pneumonia
shown
fig
patient
pneumonia
almost
alway
show
groundglass
opac
airspac
consolid
involv
either
side
lower
lung
field
chest
comput
tomographi
ct
perform
chest
ct
scan
reveal
lobar
consolid
right
lower
lobe
segment
infiltr
left
upper
lobe
patient
group
ii
show
rapid
clear
pneumon
infiltr
compar
patient
group
iii
sinc
lower
respiratori
sampl
higher
viral
load
show
sustain
viral
releas
upper
respiratori
primarili
measur
viral
load
lower
respiratori
secret
sputa
tracheal
aspir
fig
patient
secret
viru
copiesml
sputa
first
week
shed
similar
level
copiesml
virion
ten
day
fever
onset
viremia
observ
transient
viremia
copiesml
occur
day
group
ii
patient
mild
pneumonia
viral
shed
copiesml
averag
copiesml
detect
sputa
ten
day
symptom
onset
viremia
averag
copiesml
observ
ten
thirteen
day
respect
wherea
viremia
sinc
complain
sever
headach
nausea
day
cerebrospin
fluid
csf
collect
examin
inflammatori
sign
viremia
detect
evid
cn
infect
viral
shed
group
ii
patient
stop
initi
antivir
therapi
group
iii
patient
suffer
sever
pneumonia
viral
secret
lower
respiratori
tract
sustain
continu
day
follow
onset
symptom
addit
viremia
detect
serum
sampl
day
case
viral
shed
ceas
antivir
therapi
two
patient
wherea
viremia
continu
patient
initi
viral
load
respiratori
secret
second
week
rang
copiesml
howev
averag
viral
load
plasma
around
copiesml
similar
group
ii
patient
case
receiv
convalescentphas
plasma
twice
viral
load
respiratori
secret
increas
slightli
level
viremia
remain
virtual
unchang
day
viral
load
lower
respiratori
secret
fatal
case
group
iv
rel
higher
copiesml
averag
copiesml
survivor
viremia
averag
copiesml
also
sustain
antivir
therapi
group
iv
case
antibodi
respons
spike
antigen
measur
elisa
compar
among
four
group
gradual
increas
serum
igg
observ
recov
patient
regardless
diseas
sever
wherea
serum
igg
respons
gener
static
second
week
lethal
patient
fig
long
incub
period
day
show
decreas
antibodi
respons
passiv
plasma
therapi
even
though
show
highest
igg
respons
among
patient
day
effect
antivir
therapi
igg
respons
clear
also
examin
secretori
iga
respons
respiratori
secret
fig
supplementari
fig
level
antigenspecif
secretori
iga
measur
rel
od
titer
gener
increas
two
three
week
symptom
onset
reach
steadi
state
declin
recov
patient
notabl
secretori
iga
titer
group
iii
patient
rel
higher
mild
case
second
third
week
among
deceas
patient
three
patient
develop
detect
secretori
iga
second
third
week
wherea
fail
produc
specif
iga
day
level
antibodi
respons
compar
viral
load
plasma
respiratori
secret
fig
level
serum
igg
invers
correl
viral
load
plasma
respiratori
secret
although
reach
statist
signific
respiratori
viral
load
also
neg
correl
secretori
iga
level
without
statist
signific
secretori
iga
show
neg
correl
viral
load
plasma
consist
high
viral
load
clinic
sampl
even
presenc
specif
antibodi
suggest
earli
antibodi
respons
induc
system
mucos
immun
system
may
provid
suffici
protect
immun
merscov
replic
nevertheless
sinc
measur
viral
nucleic
acid
level
rather
infecti
viral
titer
clinic
sampl
exclud
possibl
viral
infect
lower
due
opson
antivir
antibodi
hematolog
chang
cours
mer
examin
patient
fig
supplementari
tabl
group
patient
signific
abnorm
observ
leukocyt
count
absolut
count
remain
within
normal
rang
note
gradual
increas
lymphocyt
platelet
week
symptom
onset
gradual
rise
lymphocyt
platelet
count
also
observ
group
ii
patient
week
symptom
onset
also
show
transient
rise
neutrophil
count
second
week
transient
persist
leukocytosi
primarili
due
increas
neutrophil
observ
among
group
iii
patient
monocyt
count
also
rose
rapidli
second
third
week
return
basal
level
thereaft
thu
recov
patient
exhibit
gradual
increas
lymphocyt
count
suggest
lymphocyt
respons
may
correl
diseas
resolut
among
five
lethal
case
neutrophilia
observ
earli
increas
lymphocyt
count
occur
group
iv
patient
except
howev
suffer
lymphopenia
thrombocytopenia
antivir
therapi
slight
increas
monocyt
count
detect
treatment
promin
differenti
chang
white
blood
cell
prompt
us
measur
cytokin
chemokin
patient
plasma
measur
cytokin
chemokin
growth
factor
differ
time
point
supplementari
tabl
substanti
elev
patient
peak
second
week
symptom
onset
fig
sinc
group
ii
iv
patient
receiv
pegyl
elev
cytokin
may
primarili
attribut
respons
therapi
gcsf
gmcsf
stimul
bone
marrow
produc
granulocyt
monocyt
also
upregul
patient
fig
supplementari
fig
moreov
gcsf
rapidli
increas
patient
die
rel
poor
gmcsf
respons
antivir
treatment
also
measur
sever
pro
anti
inflammatori
cytokin
patient
plasma
supplementari
tabl
fig
patient
pneumonia
rel
elev
cytokin
second
third
week
cytokin
gener
higher
sever
group
iii
fatal
case
group
iv
mild
case
group
ii
fig
also
interest
note
respons
promin
group
group
iii
patient
bare
detect
group
ii
group
iv
patient
fig
robust
induct
divers
chemokin
includ
fractalkin
mdc
rant
eotaxin
gro
observ
patient
although
level
express
kinet
quit
variabl
supplementari
tabl
fig
transient
upregul
promin
group
ii
iii
patient
group
iv
patient
significantli
higher
pneumonia
patient
group
ii
iv
group
patient
product
gener
wane
treatment
period
patient
recov
pneumonia
group
ii
iii
express
also
highli
induc
group
ii
iii
patient
differenti
kinet
group
ii
elev
treatment
period
increas
three
group
iii
patient
antivir
therapi
fig
chemokin
bare
induc
lethal
patient
group
iv
except
induct
gro
also
show
similar
kinet
fig
robust
induct
mdc
fractalkin
recruit
monocyt
andor
cell
inflam
tissu
may
contribut
inflammatori
respons
andor
viral
clearanc
lung
addit
chemokin
gro
may
help
recruit
neutrophil
induc
infiltr
immun
cell
infect
lung
tissu
viral
pneumonia
induct
rant
eotaxin
recruit
eosinophil
andor
basophil
detect
patient
suggest
potenti
role
innat
immun
cell
lung
inflamm
mer
patient
supplementari
tabl
fig
cytokin
regul
cell
homeostasi
function
respons
detect
patient
none
cytokin
seem
correl
diseas
sever
mortal
supplementari
tabl
supplementari
fig
key
cytokin
involv
activ
cell
consist
observ
patient
first
second
week
symptom
onset
interestingli
two
cytokin
regul
cell
homeostasi
substanti
increas
patient
particular
respons
significantli
higher
pneumonia
patient
except
group
patient
supplementari
fig
solubl
ligand
also
increas
patient
plasma
fig
sinc
cytokinelik
activ
inflammatori
respons
primarili
produc
activ
level
serum
protein
may
reflect
platelet
activ
mer
progress
inde
kinet
respons
remain
suppress
among
group
iv
patient
suffer
thrombocytopenia
fig
sever
growth
factor
egf
vegf
also
significantli
elev
plasma
mer
patient
supplementari
tabl
supplementari
fig
interest
note
level
egf
significantli
higher
recov
patient
compar
fatal
case
wherea
level
gener
higher
patient
suffer
sever
pneumonia
compar
mild
case
previous
shown
egf
protect
effect
gastrointestin
insult
porcin
epidem
diarrhea
viru
pedv
member
coronaviru
famili
potenti
via
promot
recoveri
damag
mucos
hazard
ratio
hr
mortal
accord
level
variou
virolog
immunolog
factor
shown
supplementari
tabl
overal
patient
higher
antibodi
respons
especi
respiratori
iga
lymphocyt
respons
well
lower
leukocyt
neutrophil
count
significantli
lower
hazard
ratio
mortal
merscov
infect
although
hazard
ratio
white
blood
cell
count
limit
iga
nod
hr
ci
leukocyt
count
hr
ci
neutrophil
count
hr
ci
lymphocyt
count
hr
ci
regard
cytokin
chemokin
growth
factor
patient
higher
level
well
lower
level
rant
efg
higher
hazard
ratio
mortal
margin
signific
adjust
age
hr
ci
hr
ci
hr
ci
rant
hr
ci
egf
hr
ci
addit
virolog
immunolog
factor
patient
gender
comorbid
seem
associ
mortal
morbid
although
associ
gender
mortal
statist
signific
p
potenti
due
limit
patient
number
worth
noth
twothird
patient
sever
diseas
group
group
iii
iv
men
patient
mild
diseas
group
group
ii
women
presenc
chronic
underli
ill
merscov
exposur
well
age
p
test
logrank
test
significantli
associ
mortal
find
consist
case
seri
review
rapid
wide
spread
merscov
infect
south
korea
outbreak
disastr
impact
whole
countri
highlight
limit
knowledg
mer
howev
korean
mer
case
report
well
document
transmiss
rout
expos
period
enabl
us
fine
character
diseas
progress
infect
patient
studi
system
analyz
clinic
virolog
immunolog
respons
group
patient
collect
repres
broad
spectrum
mer
sever
mild
febril
fatal
although
number
patient
includ
studi
limit
data
help
clearli
delin
mer
progress
human
also
provid
scientif
basi
better
prevent
measur
addit
observ
respons
multipl
factor
associ
diseas
sever
therapeut
period
might
help
us
develop
proper
strategi
improv
efficaci
current
mer
treatment
fourteen
patient
could
readili
classifi
four
clinic
group
base
diseas
sever
mortal
group
patient
produc
merscov
copiesml
sputa
day
fever
onset
consid
long
incub
period
day
viral
shed
may
preced
onset
fever
therefor
earli
diagnosi
quarantin
person
contact
mer
patient
may
requir
prevent
merscov
spread
even
asymptomat
mild
symptom
sinc
secretori
iga
specif
spike
antigen
increas
respiratori
tract
day
symptom
onset
merscov
specif
mucos
antibodi
respons
may
potenti
diagnost
biomark
mild
case
earli
diseas
cours
among
patient
develop
pneumonia
complet
recov
mer
effect
viral
clearanc
achiev
antivir
therapi
group
ii
patient
wherea
sustain
viral
secret
observ
especi
blood
group
iii
patient
even
follow
antivir
therapi
consid
viral
shed
poorli
control
fatal
case
possibl
limit
proport
mer
patient
respond
current
antivir
regimen
merscov
receptor
dipeptidylpeptidas
express
greater
abund
lung
parenchyma
alveolar
type
ii
cell
macrophag
vascular
endothelia
upper
airway
conduct
airway
addit
express
induc
may
increas
chronic
diseas
specul
higher
respiratori
tract
viru
shed
observ
sever
fatal
case
may
reflect
normal
distribut
increas
receptor
abund
associ
chronic
diseas
state
patient
develop
virusspecif
serum
igg
secretori
iga
respiratori
tract
except
one
fatal
case
fail
develop
secretori
iga
consist
recent
antibodi
respons
blood
well
respiratori
tract
survivor
sustain
elev
fatal
case
although
measur
neutral
activ
antibodi
respons
report
specif
elisa
valu
gener
correl
neutral
antibodi
nevertheless
viral
shed
detect
presenc
specif
antibodi
respons
suggest
weak
protect
effect
viral
replic
primari
merscov
patient
receiv
convalescentphas
plasma
show
signific
chang
blood
respiratori
tract
viral
load
subsequ
sever
day
follow
treatment
fig
rather
serum
igg
respons
rapidli
drop
plasma
therapi
fig
although
could
explain
unexpect
respons
consist
report
korean
patient
given
plasma
therapi
show
delay
antibodi
respons
day
follow
treatment
compar
although
systemat
studi
patient
receiv
plasma
therapi
need
find
suggest
passiv
antibodi
transfer
may
limit
efficaci
previou
report
plasma
therapi
sar
patient
show
benefit
achiev
subset
patient
administ
within
day
onset
one
promin
factor
associ
mer
diseas
sever
outcom
hematolog
chang
leukocyt
popul
fig
gradual
persist
increas
lymphocyt
count
mer
progress
observ
survivor
wherea
deceas
patient
show
rapid
drop
lymphocyt
count
second
week
result
lymphopenia
contrast
lymphocyt
count
rapidli
increas
day
symptom
onset
group
patient
one
group
ii
patient
strongli
suggest
adapt
immun
respons
play
protect
role
patient
recov
pneumonia
group
ii
iii
kinet
lymphocyt
respons
rather
delay
gener
correl
resolut
viral
pneumonia
elev
chemokin
includ
fractalkin
rant
recruit
lymphocyt
may
contribut
cellmedi
antivir
respons
inflam
tissu
among
rant
rapidli
elev
first
week
group
patient
rather
delay
robustli
induc
group
ii
iii
patient
fig
chemokin
also
increas
group
iv
patient
gener
weaker
recov
patient
increas
level
supplementari
fig
first
second
week
also
support
antivir
cell
respons
inflam
recent
shown
cytokin
chemokin
activ
express
merscovinfect
dendrit
cell
nevertheless
cytokin
associ
function
activ
specif
subset
cell
bare
detect
studi
instead
elev
differenti
kinet
note
associ
elev
inflammatori
pulmonari
diseas
previous
report
well
merscov
infect
addit
leukocytosi
character
increas
neutrophil
monocyt
primarili
observ
sever
group
iii
iv
patient
suggest
innat
immun
cell
respons
rather
antivir
respons
might
respons
mer
pathogenesi
lung
elev
gcsf
second
third
week
especi
fatal
case
may
account
observ
leukocytosi
although
chemokin
involv
recruit
neutrophil
monocyt
highli
elev
group
ii
iii
patient
suffer
pneumonia
overal
chemokin
respons
except
rel
reduc
fatal
case
addit
specif
correl
chemokin
level
diseas
mortal
observ
among
inflammatori
cytokin
examin
level
acut
phase
gener
absolut
associ
diseas
sever
wherea
antiinflammatori
cytokin
significantli
correl
diseas
mortal
supplementari
tabl
previous
shown
ard
caus
sarscov
infect
associ
induct
inflammatori
cytokin
chemokin
mani
highli
express
lung
sar
interestingli
respons
elev
group
iii
patient
consid
involv
antibodi
class
switch
wound
heal
scar
format
via
fibrosi
well
suppress
adapt
immun
respons
lung
differenti
express
cytokin
mer
patient
might
link
diseas
sever
andor
protect
viral
infect
nevertheless
sinc
preexist
comorbid
especi
group
iv
like
contribut
observ
variat
cytokin
chemokin
mer
progress
may
need
care
interpret
result
associ
chemokin
cytokin
diseas
sever
mortal
conclus
analyz
divers
virolog
immunolog
factor
may
affect
sever
progress
outcom
mer
welldefin
clinic
set
high
viral
load
weak
antibodi
respons
lymphopenia
accompani
thrombocytopenia
associ
diseas
mortal
wherea
persist
lymphocyt
respons
might
requir
effect
immun
merscov
infect
leukocytosi
primarili
due
increas
neutrophil
monocyt
gener
observ
sever
fatal
case
blood
level
cytokin
egf
correl
diseas
sever
robust
induct
variou
chemokin
gro
rant
differenti
kinet
promin
patient
recov
pneumonia
patient
mild
febril
ill
deceas
patient
although
number
patient
studi
limit
correl
viru
shed
immunolog
respons
diseas
sever
mortal
well
respons
current
antivir
therapi
may
indic
prognost
signific
acut
phase
symptom
onset
studi
function
relationship
factor
effect
immun
pathogenesi
mer
need
conduct
clinic
data
specimen
obtain
mer
patient
use
studi
ethnic
approv
grant
institut
review
board
chungnam
nation
univers
hospit
seoul
nation
univers
hospit
studi
perform
accord
ethic
standard
laid
declar
helsinki
subsequ
revis
surviv
patient
provid
written
inform
consent
particip
fatal
case
obtain
exempt
patient
consent
institut
review
board
retrospect
analysi
clinic
sampl
merscov
infect
confirm
fourteen
patient
treat
chungnam
nation
univers
hospit
june
august
posit
realtim
rtpcr
assay
target
upe
sequenc
korean
center
diseas
control
laboratori
review
clinic
inform
daili
find
histori
physic
examin
puls
oximetri
haematolog
biochem
radiolog
investig
clinic
specimen
collect
viral
diagnosi
includ
respiratori
secret
blood
cerebrospin
fluid
ascit
fluid
mer
patient
use
quantif
specif
antibodi
subset
cytokin
viral
load
pneumonia
sever
index
psi
use
estim
sever
pneumonia
patient
describ
classifi
patient
four
group
base
diseas
sever
mortal
perform
compar
analysi
total
rna
extract
respiratori
sampl
includ
sputa
tracheal
aspir
plasma
use
trizol
ls
reagent
thermo
fisher
scientif
accord
manufactur
instruct
rna
sampl
use
titrat
viral
genom
use
quantit
realtim
rtpcr
kit
cosmogenetech
co
kogenebiotech
amplifi
upe
viral
copi
number
estim
compar
ct
valu
sampl
dilut
posit
control
viral
cdna
accord
manufactur
instruct
cosmogenetech
co
hand
detect
limit
viral
copi
number
copiesml
target
copiesml
upe
use
target
triplic
result
show
consist
posit
reaction
copi
number
data
use
kinet
analysi
even
detect
limit
otherwis
data
regard
neg
specif
antibodi
respons
merscov
spike
protein
domain
measur
elisa
use
recombin
merscov
spike
protein
domain
accord
manufactur
instruct
antimerscov
elisa
kit
alpha
diagnost
intern
specif
igg
respons
determin
unitml
compar
net
od
valu
plasma
sampl
calibr
standard
assay
togeth
experiment
set
alpha
diagnost
intern
secretori
iga
respons
also
semiquantit
titrat
use
serial
dilut
respiratori
sampl
use
elisa
kit
substitut
antihuman
igahorseradish
peroxidas
conjug
southernbiotech
secondari
sinc
lower
respiratori
tract
sampl
sputa
difficult
analyz
directli
process
perform
elisa
describ
due
limit
sampl
antibodi
respons
measur
day
interv
data
obtain
includ
kinet
analysi
thirti
eight
cytokin
chemokin
growth
factor
measur
plasma
sampl
use
milliplex
map
cytokin
assay
kit
millipor
specifi
manufactur
instruct
includ
vegf
mdc
gro
gmcsf
gcsf
fractalkin
l
eotaxin
egf
rant
measur
independ
use
quantit
elisa
kit
biolegend
sampl
measur
duplic
mean
valu
use
analysi
data
patient
arrang
date
exposur
infect
patient
date
death
event
n
date
recov
patient
discharg
hospit
censor
case
n
supplementari
fig
perform
timevari
analys
data
valu
obtain
patient
sampl
total
individu
observ
depend
number
measur
virolog
immunolog
factor
observ
period
coxproport
hazard
regress
model
virolog
immunolog
factor
enter
time
vari
covari
use
calcul
crude
hazard
ratio
hr
confid
interv
ci
factor
per
unit
mortal
factor
treat
continu
variabl
ageadjust
hazard
ratio
calcul
everi
factor
studi
pvalu
less
twotail
consid
statist
signific
statist
analys
perform
stata
version
stata
co
statist
analys
correl
antibodi
respons
viral
load
perform
linear
regress
assay
embed
graphpad
prism
softwar
ver
cite
articl
min
ck
et
al
compar
kinet
analysi
viral
shed
immunolog
respons
mer
patient
repres
broad
spectrum
diseas
sever
sci
rep
doi
